Michael Amoroso left the role of Director at Abeona Therapeutics Inc. As of November 6, 2026, Abeona Therapeutics Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 7, 2026 to June 12, 2026, naming 2 appointments and 2 departures (Form 8-K, June 12, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Abeona Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Abeona Therapeutics Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-07 to 2026-06-12. They name 2 people, with 2 appointments and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Abeona Therapeutics Inc. files it.
Also on the record for Abeona Therapeutics Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 23, 2026 | Stake report, Schedule 13D, by James Russell Revocable Trust | 6.1% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Montanova Capital, LLC | 0.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Nantahala Capital Management, LLC | 9.99% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP | 5.82% of the class | 5%+ stakes | Source |
| April 28, 2026 | Stake report, Schedule 13G, by Orin Hirschman | 5.4% of the class | 5%+ stakes | Source |
| April 6, 2026 | Stake report, Schedule 13G, by Funicular Funds, LP | 5.3% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G, by Daniel Kaufman | 5.16% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G/A, by Adage Capital Management, L.P. | — | 5%+ stakes | Source |
| November 13, 2025 | Stake report, Schedule 13G/A, by Adage Capital Management, L.P. | 9.99% of the class | 5%+ stakes | Source |
| October 30, 2025 | Stake report, Schedule 13G, by The Vanguard Group | 5.07% of the class | 5%+ stakes | Source |
| October 6, 2025 | Stake report, Schedule 13G, by NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP | 5.09% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Abeona Therapeutics Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Abeona Therapeutics Inc. and the records around it.
Abeona Therapeutics Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Daniel Kaufman also filed stake reports on 6 other companies: AUNA S.A. (May 2026), DELCATH SYSTEMS, INC. (Mar 2026), i-80 Gold Corp. (Jan 2026)
- NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP also filed stake reports on 6 other companies: FEMASYS INC. (Aug 2026), AZITRA, INC. (Aug 2026), KIORA PHARMACEUTICALS, INC. (May 2026)
- Funicular Funds, LP also filed stake reports on 10 other companies: AmpliTech Group, Inc. (Oct 2026), SYNLOGIC, INC. (Jul 2026), Rein Therapeutics, Inc. (May 2026)
Watch Abeona Therapeutics Inc.
Get an email when Abeona Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Abeona Therapeutics Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Abeona Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Abeona Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 16 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-12 | Out | Director | 8-K, 2026-06-12 | ||
| 2026-06-12 | Out | 8-K, 2026-06-12 | |||
| 2026-04-07 | In | Director | 8-K, 2026-04-07 | ||
| 2026-04-07 | In | 8-K, 2026-04-07 |
Who leads Abeona Therapeutics Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Michael Amoroso, departure reported (filed 2026-06-12). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Abeona Therapeutics Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Abeona Therapeutics Inc., with the record behind each one.
Find candidates like Director at Abeona Therapeutics Inc.Every change, in the filing's words
Departing: Michael Amoroso, Director
On June 11, 2026, Michael Amoroso resigned as a member of the Board of Directors (the "Board") of Abeona Therapeutics Inc. (the "Company") effective immediately.
Departing: Michael Amoroso
In connection with his resignation, Mr. Amoroso also resigned from the Nominating and Corporate Governance Committee of the Board on which he served.
- Mr. Amoroso's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices but solely for personal reasons.
Appointed: Keith A. Goldan, Director
On April 1, 2026, the Board of Directors (the "Board") of Abeona Therapeutics Inc. (the "Company"), acting upon the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Board from nine to ten members and appointed Keith A. Goldan as a member of the Board of the Company as a Class 1 director.
Appointed: Keith A. Goldan
The Board also appointed Mr. Goldan to serve as Chair of the Audit Committee.
- Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
- Mr. Goldan will serve on the Board for a term expiring at the Company's 2026 annual meeting of stockholders.
- The Board determined that Mr. Goldan is an independent director under applicable Nasdaq listing rules.
- Mr. Goldan will receive an annual Board fee of $50,000 in cash and a one-time sign-on equity grant in the amount of $150,000 worth of Company stock, in the form of restricted stock awards with a one-year vesting period.
- Mr. Goldan will be eligible for the Board's next regular equity grant in 2027, which is determined annually by the Board upon recommendation of the Compensation Committee of the Board, based on the advice of an external compensation consultant.
Tools for this story
Each opens in a new tab, filled in for Abeona Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.